|
© 2004 American Academy of Neurology Brief Communications Markedly elevated GAD antibodies in SPSEffects of age and illness durationFrom the Department of Neurology (Dr. Murinson), Johns Hopkins School of Medicine, Baltimore, MD; Boyer Center for Molecular Medicine (Drs. Butler and De Camilli) and Howard Hughes Medical Institute (Dr. De Camilli), Yale University School of Medicine, New Haven, CT; Bayer Diagnostics Division (Dr. Gleason, K. Marfurt), Elkhart, IN; and Faculty of Medicine (Dr. Solimena), Medizinisch Theoretisches Zentrum, Faculty of Medicine, TU-Dresden, Germany. Address correspondence and reprint requests to Dr. B.B. Murinson, 509 Pathology, 600 N. Wolfe St., Baltimore, MD 21287; e-mail: Bmurins1{at}jhmi.edu Five hundred seventy-six patients with suspected stiff-person syndrome (SPS) underwent immunocytochemistry (ICC). Of these, 286 underwent radioimmunoassay (RIA) for glutamic acid decarboxylase (GAD) antibodies; 116 were GAD antibody positive by one or both tests. Ninety-six percent of those positive by ICC had RIA values several standard deviations above normal. RIA did not correlate with age or illness duration. Marked elevations of RIA for GAD antibodies were characteristic of ICC-confirmed SPS, and modest elevations were not.
Received March 4, 2004. Accepted in final form August 10, 2004. Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the December 14 issue to find the title link for this article. See also page 1999 K. Marfurt and Dr. Gleason are employees of Bayer Corporation. Drs. Solimena and De Camilli hold US patent no. 5,512,447 on the detection of glutamic acid decarboxylase autoantibodies.
Related Articles
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||